COVERSYL PLUS TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

PERINDOPRIL ERBUMINE; INDAPAMIDE

Beschikbaar vanaf:

SERVIER CANADA INC

ATC-code:

C09BA04

INN (Algemene Internationale Benaming):

PERINDOPRIL AND DIURETICS

Dosering:

4MG; 1.25MG

farmaceutische vorm:

TABLET

Samenstelling:

PERINDOPRIL ERBUMINE 4MG; INDAPAMIDE 1.25MG

Toedieningsweg:

ORAL

Eenheden in pakket:

30

Prescription-type:

Prescription

Therapeutisch gebied:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0248401001; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2003-07-04

Productkenmerken

_ _
_COVERSYL_
_®_
_ PLUS LD / COVERSYL_
_®_
_ PLUS / COVERSYL_
_®_
_ PLUS HD _
_(perindopril erbumine / indapamide) Product Monograph _
_Page 1 of 65_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
COVERSYL® PLUS LD
Tablets, 2 mg / 0.625 mg Oral
Pr
COVERSYL® PLUS
Tablets, 4 mg / 1.25 mg Oral
Pr
COVERSYL® PLUS HD
Tablets, 8 mg / 2.5 mg Oral
perindopril erbumine / indapamide
Angiotensin Converting Enzyme Inhibitor / Diuretic
Servier Canada Inc.
3224 Avenue Jean-Béraud #270
Laval, Quebec, H7V 2S4
Date of Initial Authorization:
October 4, 2002
Date of Revision:
October 21, 2022
Submission Control Number: 264225
_ _
_COVERSYL_
_®_
_ PLUS LD / COVERSYL_
_®_
_ PLUS / COVERSYL_
_®_
_ PLUS HD _
_(perindopril erbumine / indapamide) Product Monograph _
_Page 2 of 65_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
10/2022
7 WARNING AND PRECAUTIONS
10/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES................................................ Error!
Bookmark not defined.
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics (< 18 years of
age)..............................................................................
4
1.2
Geriatrics (> 65 years of age)
..............................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Consi